Rezera (RZRA) investor relations material

Company overview and business model

• Clinical-stage biotech developing wholly owned oral NLRP3 inhibitors; ruvonoflast is designed for peripheral and brain penetration, while trabzanoflast is optimized for CNS exposure.

• Strategy prioritizes ruvonoflast in PAD, followed by broader ASCVD development; trabzanoflast is planned for a Phase 2 neuroinflammation proof-of-concept trial.

• All product candidates retain exclusive worldwide development and commercialization rights; future growth may include internal discovery, in-licensing, acquisitions and partnerships.

Financial performance and metrics

• H1 2026 R&D expense was $19.9M vs. $10.3M H1 2025; G&A was $4.7M vs. $3.6M, and net loss was $25.5M vs. $13.7M.

• FY2025 net loss was $42.2M vs. $25.2M FY2024; accumulated deficit reached $210.7M at June 30, 2026, with no drug-sales revenue to date.

• Cash and equivalents were $3.9M at June 30, 2026; July 2026 financing added ~$15.0M net from Series D4 and a fully drawn $15.0M term loan, supporting operations into January 2027.

• Recurring losses and negative operating cash flows led management to conclude substantial doubt exists about the ability to continue as a going concern for one year following the interim financial statements.

Use of proceeds and capital allocation

• IPO proceeds, together with existing cash, Series D4 proceeds and the term loan, are intended to fund ruvonoflast’s proposed PAD Phase 3 trial, commercial readiness if approved, earlier-stage pipeline development, working capital and general corporate purposes.

• Proceeds are not expected to fund development through regulatory approval; additional capital will be required, and management retains broad discretion over allocation.